

DETECTION OF REACTIVATION OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS

Thesis

Submitted in partial fulfilment of the Ph.D. degree in Medical Microbiology
and Immunology

Investigator

Reham Ali Fahmi Dewdar

M.B.B.Ch., M.Sc., Cairo University

Assistant lecturer of Medical Microbiology and Immunology

Faculty of Medicine, Cairo University

Supervised by

Professor Mona Abdel Wahab Abdel Mesih

Professor of Medical Microbiology and Immunology

Faculty of Medicine – Cairo University

Professor Dawlat Mohamad Abdel Hamid

Professor of internal medicine

Faculty of Medicine – Cairo University

Dr. Iman Ezzat Wali

Assistant Professor of Medical
Microbiology and Immunology

Faculty of Medicine

Cairo University

Dr. Ashraf Elsayed Abdel Hamid

Assistant Professor of Medical
Microbiology and Immunology

Faculty of Medicine

Cairo University

Faculty of Medicine

Cairo University

2009

سُورَةُ الْبَقَرَةِ

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا

سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ



ACKNOWLEDGEMENT

أَنِ اشْكُرْ لِي وَلِوَالِدَيْكَ إِلَى الْمَصِيرِ
سورة لقمان - الآية ١٤

First of all, always and forever, thanks are due to **Allah**, the most merciful, and the mightiest, for all his great continuous gifts, those we feel and those we cannot feel.

This work would not have been possible without the support and encouragement of **Professor Mona Abdel Wahab Abdel Mesih**, professor of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, under whose supervision I chose this topic and began the thesis. She has been abundantly helpful, and assisted me in numerous ways. I am so greatly indebted to her.

I would like to express my gratitude to **Professor Dawlat Mohamad Abdel Hamid**, professor of Internal Medicine, Faculty of Medicine, Cairo University, for her supervision, advice, guidance especially in the clinical part of this work.

I greatly acknowledge **Dr. Iman Ezzat Wali**, assistant professor of Medical Microbiology and Immunology, Cairo University, for her advice, supervision, crucial contribution, as well as giving me extraordinary experiences throughout the work.

I greatly acknowledge **Dr. Ashraf Elsayed Abdel Hamid**, assistant professor of Medical Microbiology and Immunology, Cairo University, for his thorough reviewing and sustained efforts in bringing this work to its final version.

Truly no words could express my gratitude and appreciation for **Professor Azza E. Badr**, professor of Medical Microbiology and Immunology, Faculty of

Medicine, Cairo University who was so generous with me with her scientific knowledge and caring nature.

I would like to thank ***Professor Marie Abdel Aziz***, professor of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, a man with an innovative mind, for his help with the idea of this work.

I am also very grateful to ***Dr. Manal Mohamad Nabeeh El-Deeb***, assistant professor of Internal Medicine, Cairo University for her kind supervision and guidance, especially in the clinical aspects, in spite of not being directly involved in this work.

I would like to acknowledge the help of ***Mr. Hussien Mohamad*** and ***Mr. Ahmad Hassan*** from the Molecular Hepatology Unit, Mahmoud Mosque Society for their technical support in the PCR procedure.

I would like to acknowledge the help of the nursing staff especially Miss Azza and the secretary of ***the renal transplantation unit, New Kasr El Aini Teaching Hospital*** for helping me in collecting the patients' samples and data.

To ***all my respectable professors, staff members and colleagues at the Department of Medical Microbiology and Immunology, Cairo University***, to whom I belong, I am deeply grateful.

No words can express my appreciation to ***my husband*** whose dedication and persistent confidence in me, has taken the load off my shoulder. I cannot end without thanking ***my parents and my sister***, on whose constant encouragement and love I have relied throughout my life. Last, but not the least, I would like to thank ***my children*** who gave a meaning to my life.

Reham Ali Dewdar

Abstract

Background: Cytomegalovirus infection in renal transplant recipients is a major clinical problem that may cause significant morbidity and mortality. Infection can occur as a result of reactivation of latent virus or new infection from donor tissues.

Objectives: To assess the incidence of cytomegalovirus (CMV) reactivation, and to determine the predictive factors for CMV reactivation in renal-transplant patients also to compare CMV-DNA amplification using qRT-PCR with serologic assays of CMV-IgM antibodies to detect CMV reactivation.

Study design: Sixty patients were included in this study. They were classified into 3 groups based on the post transplantation period during which the study was performed. ELISA was used to detect the pre-transplantation CMV serostatus for the donor and the recipient as well as the recipient post transplantation CMV serology. CMV DNAemia was assessed by qRT-PCR first on whole blood (WB). Whenever a positive result was obtained; the assay was then performed on plasma to detect the difference between them.

Results: CMV reactivation occurred in two patients following the treatment of their rejection episode and was detected by qRT-PCR using whole blood and not in plasma.

Conclusion: Cytomegalovirus reactivation was not high in the studied patients, which may be due to the presence of pre -existing immunity in the form of neutralizing antibody, and that treatment of an episode of acute allograft rejection was the most important risk for CMV reactivation within the first year post-transplantation. qRT-PCR is an important tool in predicting subsequent or ongoing disease, while detection of anti CMV-IgM antibodies is not sensitive enough for diagnosis

Keywords: Cytomegalovirus, Kidney Transplantation, Reactivation, Acute rejection, Immunosuppressive therapy.

List of Contents

	Page
List of abbreviations.....	I
List of tables.....	VI
List of figures.....	VII
Introduction.....	1
Aim of the work.....	3
Review of literature.....	4
<i>I - Infectious complications in kidney transplant recipients.....</i>	<i>4</i>
<i>II – Cytomegalovirus.....</i>	<i>21</i>
Patients and methods.....	56
Results.....	75
Discussion.....	89
Conclusion and recommendation.....	105
Summary.....	107
Appendix.....	110
References.....	113
Arabic Summary.....	

List Of Abbreviations

Ab	Antibody
ADCC	Antibody-dependent cell-mediated cytotoxicity
Ag	Antigen
AIDS	Acquired immune deficiency syndrome
ALG	Antilymphocytic globulin
ALL	Acute lymphoblastic leukemia
AP	Assembly protein
BKV	BK virus
BMT	Bone marrow transplantation
CARI	Caring for Australians with Renal Impairment
CD	Clusters of differentiation
CDV	Cidofovir
CMV	Cytomegalovirus
CNS	Central nervous system
CP	crossing point
CPE	Cytopathic effect
CsA	Cyclosporin A
C _T	Threshold cycle
CTL	Cytotoxic T-cell
CVS	Cardiovascular system
D/R	Donors/recipients

DB	Dense bodies
DM	Diabetes Mellitus
DMSO	Dimethyle sulfoxide
DNA	Deoxyribonucleic Acid
dNTP	desoxynucleoside triphosphate
dTTP	desoxythimidine triphosphate
dUTP	desoxyuridine triphosphate
EBV	Epstein-Barr virus
EDTA	Ethylene-diamine-tetraacetic acid
EHV1	Equine Herpesvirus
ELISA	Enzyme-linked immunosorbent assay
ER	Endoplasmic reticulum
ESRD	End stage renal disease
FRET	Fluorescence resonance energy transfer
gB gene	Glycoprotein B gene
GC	Guanine & Cytosine
GCV	Gancyclovir
H&E	Hematoxylin and eosin, a standard tissue stain
H ₂ O	Water
H ₂ O ₂	Hydrogen peroxide
H ₂ SO ₄	Sulpheric acid
HAART	Highly active anti-retroviral therapy
HBV	Hepatitis B Virus
HCMV	Human cytomegalovirus

HCV	Hepatitis C Virus
HD	Hemodialysis
HHV	Human herpesvirus
HHV-8	Human herpesvirus 8
HIV	Human Immunodeficiency Virus
HLA	Human leukocyte antigen
Hr	Hour
HRPO	Horse radish peroxidase
HSCT	Haematopoietic stem cell transplant
HSV	Herpes Simplex Virus
HVS	Herpesvirus Saimiri
IE genes	Immediate early genes
IF	Immunofluorescence
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IHMF	The International Herpes Management Forum.
INF(- α)	Interferons - α
IU	International unit
Kbp.	Kilo base pair
KS	Kaposi's sarcoma
L genes	Late genes
Lab	Laboratory
LED	Light emitting diode

MGPs	Magnetic glass particles
MHC	Major histocompatibility complex
MIE gene	Major immediate-early gene
ml	Milliliter
MMF	Mycophenolate mofetil
mmol/L	Millimols per litre
NK cells	Natural killer cells
N ^o	Number
°c	Degree Celsius
OKT3	Orthoclone
PBLs	Peripheral blood leukocytes
PBMCs	Peripheral blood mononuclear cells
PCR	Polymerase chain reaction
PD	Peritoneal dialysis
PFA	Pyrophosphate analogue
pp	Phosphoprotein
PRV	Pseudorabies virus
PVAN	Polyomavirus-associated nephropathy
Qn PCR	quantitative PCR
RBC	Red blood cells
RNA	Ribonucleic acid
RPR	Rapid plasma regain
RT- PCR	Real-time polymerase chain reaction
RTR	Renal transplant recipients

SCT	Stem cell transplant
SE	Standard error of the mean
SOT	Solid organ transplant
SPSS	Statistical Product and Service Solutions (formerly Statistical Package for Social Sciences).
TMB	Tetramethyl benzidine
TST	Tuberculin skin test
UL	Unique long
US	Unique short
UTI	Urinary tract infection
vICA	Viral inhibitor of caspase-8 induced apoptosis
vMIA	Viral mitochondrial inhibitor of apoptosis
WB	Whole blood
WBC	White Blood Cell, White Blood Cell Count
WHO	World Health Organisation
µg	Microgram

List Of Tables

Table N^o:	Legend	Page
Table 1	Strategies for chemotherapy of CMV.....	55
Table 2	Preparation of the master mix.....	69
Table 3	Characteristics of patients in the studied groups.....	76-77
Table 4	Characteristics of patients who suffered from rejection episodes	86

List Of Figures

Figure N ^o	Legend	Page
Figure 1	Cytomegalovirus Structure.....	24
Figure 2	CMV 's typical "owl's eye" appearance of the infected cell nucleus.....	29
Figure 3	CMV replicative cycle.....	30
Figure 4	Geographical distribution of CMV.....	34
Figure 5	CMV infection rates in transplant patients.....	37
Figure 6	Overview of CMV infection: direct & indirect effects.....	41
Figure 7	HCMV pp65 immunofluorescence detection on infected poly-morpho nuclear cells isolated from peripheral blood...	45
Figure 8	MagNA pure compact instrument, Benchtop instrument for fully automated nucleic acid purification.....	63
Figure 9	Overview of nucleic acid isolation and purification with the MagNA pure LC system.....	65
Figure 10a	Schematic diagram of the hybridization probes.....	67
Figure 10b	Example of FRET probes.....	68
Figure 11	Roche light cycler instrument.....	70
Figure 12a	PCR amplification curve..... • An early background phase, • An exponential growth phase and a plateau phase.	72
Figure 12b	PCR amplification curve showing the threshold cycle.....	72
Figure 13	Realtime PCR standard curve.....	73
Figure 14	Sex distribution in the studied patients.....	75
Figure 15	Causes of renal transplantation in the studied patients.....	78
Figure 16	Percentage of patients regarding the duration of renal dialysis.....	78
Figure 17	Percentage of patients regarding history of previous blood transfusion.....	79
Figure 18	Distribution of HCV &/or HBV among the studied patients.....	80
Figure 19	Distribution of patients regarding their immunosuppressive regimen.....	80

Figure 20	Post- transplantation serostatus of anti-CMV IgM in the studied groups.....	81
Figure 21	Distribution of positive post- transplantation anti-CMV IgM in the studied groups.....	82
Figure 22	The amplification curve of the positive control and the two positive cases.	83
Figure 23	Representative example of the negative amplification plot...	83
Figure 24	Distribution of patients with positive CMV -DNA measured post- transplantation in the studied groups.....	84
Figure 25	% of HCV patients with +ve CMV real-time PCR and those with -ve CMV real-time PCR.....	85
Figure 26	% of patients treated by CsA with +ve CMV real-time PCR and those treated by CsA with -ve CMV real-time PCR.....	86
Figure 27	Percentage of patients who suffered from rejection episode.....	87
Figure 28	Distribution of patients who suffered from rejection episodes in the studied groups.....	87
Figure 29	Distribution of patients with positive and negative CMV – DNA in correlation with rejection episodes.....	88
Figure 30	Distribution of rejection episodes among HCV&/or HBV patients.....	88

INTRODUCTION

INTRODUCTION

AIM OF WORK

AIM OF WORK